Results 231 to 240 of about 2,027,828 (376)
A mouse model for vascular normalization and a human breast cancer cohort were studied to understand the relationship between vascular leakage and tumor immune suppression. For this, endothelial and immune cell RNAseq, staining for vascular function, and immune cell profiling were employed.
Liqun He +8 more
wiley +1 more source
To Teach or Not to Teach: Incentives and Barriers Impacting Clinical Preceptorship in Family Medicine. [PDF]
Mechling D +4 more
europepmc +1 more source
Competitive space foresight: Incentivizing compliance through antitrust
Maria Lucas-Rhimbassen, Lucien Rapp
openalex +1 more source
Liquid biopsy epigenetics: establishing a molecular profile based on cell‐free DNA
Cell‐free DNA (cfDNA) fragments in plasma from cancer patients carry epigenetic signatures reflecting their cells of origin. These epigenetic features include DNA methylation, nucleosome modifications, and variations in fragmentation. This review describes the biological properties of each feature and explores optimal strategies for harnessing cfDNA ...
Christoffer Trier Maansson +2 more
wiley +1 more source
ICU Nurses' Views on the Potential Design and Anticipated Consequences of a Hypothetical Pay-for-Performance (P4P) Program in Greece: An Exploratory Qualitative Study. [PDF]
Kosmidis D +5 more
europepmc +1 more source
Competition and Incentives with Motivated Agents
T. Besley, Maitreesh Ghatak
semanticscholar +1 more source
Intein‐based modular chimeric antigen receptor platform for specific CD19/CD20 co‐targeting
CARtein is a modular CAR platform that uses split inteins to splice antigen‐recognition modules onto a universal signaling backbone, enabling precise, scarless assembly without re‐engineering signaling domains. Deployed here against CD19 and CD20 in B‐cell malignancies, the design supports flexible multi‐antigen targeting to boost T‐cell activation and
Pablo Gonzalez‐Garcia +9 more
wiley +1 more source
Equitable access to essential medicines to treat neglected tropical diseases: Latest developments from the World Health Organization (WHO). [PDF]
Fattah F +4 more
europepmc +1 more source
Clinical trials on PARP inhibitors in urothelial carcinoma (UC) showed limited efficacy and a lack of predictive biomarkers. We propose SLFN5, SLFN11, and OAS1 as UC‐specific response predictors. We suggest Talazoparib as the better PARP inhibitor for UC than Olaparib.
Jutta Schmitz +15 more
wiley +1 more source

